On this World Diabetes Day, Adalvo showcases the strides made in the realm of diabetic care. Rooted in our commitment to patient well-being, Adalvo stands as one of the leading B2B companies offering a comprehensive diabetes portfolio, consisting of both injectables and oral solutions.
Diabetes presents a global healthcare challenge, and Adalvo proudly addresses this pressing issue with a portfolio of a combined global market size of$54 billion in 2022, with CAGR of 26%, as reported by IQVIA.
Adalvo's portfolio includes an extensive range of dossiers, spanning various domains, including, but not limited to:
Adalvo remains committed in expanding their portfolio within the diabetes care domain.
Join us on this World Diabetes Day as we celebrate our ongoing journey in redefining diabetes care.
Partner up now!
At Adalvo, there are no half measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
Reach out to your preferred Business Partner below to access Adalvo's Endocrinology dossiers.
firstname.lastname@example.org - Head of Global BD&L
email@example.com - LATAM (exc. Brazil)
firstname.lastname@example.org - South Europe
email@example.com – Central & Eastern Europe, Russia & CIS#
firstname.lastname@example.org - Brazil
email@example.com- North Europe, APAC, MENA & Israel
firstname.lastname@example.org - Central and Western Europe
email@example.com – Europe
firstname.lastname@example.org – UK/Ireland, North America & South Africa
Click on your preferred Business Partner and get in touch today!